Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) and Prenetics Global (NASDAQ:PRE – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.
Valuation and Earnings
This table compares Neuphoria Therapeutics and Prenetics Global”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Neuphoria Therapeutics | $15.65 million | 1.39 | -$370,000.00 | ($4.88) | -0.83 |
| Prenetics Global | $30.62 million | 8.92 | -$46.30 million | ($2.03) | -8.00 |
Insider and Institutional Ownership
15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 25.0% of Prenetics Global shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Neuphoria Therapeutics and Prenetics Global’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Neuphoria Therapeutics | N/A | -53.17% | -36.15% |
| Prenetics Global | -60.70% | -30.12% | -23.87% |
Risk and Volatility
Neuphoria Therapeutics has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Prenetics Global has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Neuphoria Therapeutics and Prenetics Global, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neuphoria Therapeutics | 2 | 0 | 2 | 0 | 2.00 |
| Prenetics Global | 1 | 0 | 1 | 0 | 2.00 |
Neuphoria Therapeutics currently has a consensus price target of $21.00, suggesting a potential upside of 421.09%. Prenetics Global has a consensus price target of $32.00, suggesting a potential upside of 97.17%. Given Neuphoria Therapeutics’ higher possible upside, analysts plainly believe Neuphoria Therapeutics is more favorable than Prenetics Global.
Summary
Neuphoria Therapeutics beats Prenetics Global on 7 of the 13 factors compared between the two stocks.
About Neuphoria Therapeutics
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
About Prenetics Global
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.
Receive News & Ratings for Neuphoria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
